Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nanobac Pharmaceuticals has entered into an agreement and started work on an animal model to validate a previous proof of concept study finding that calcifying nanoparticles, also known as nanobacteria, promote gallstones.
Subscribe to our email newsletter
If the proof is validated, it will solve the ages-old mystery of what provokes black pigment gallstones, and, Nanobac hopes, forge a path to effective early diagnosis and therapy where none are presently available. Results are expected by year-end 2006.
As these gallstones contain material similar to that in kidney stones and breast cancer calcifications, the results could apply to other unsolved calcification-related conditions as well.
The agreement was signed with the scientific team who recently published a paper stating that calcifying nanoparticles, or CNPs, promote black pigment gallstones in rabbits when injected into the gallbladder.
Florida-headquartered Nanobac is the only company with regulatory approval of diagnostics that can accurately identify these calcifying particles. The life sciences company said that it is also expecting to start a clinical trial on a promising therapy for such stone-forming diseases by the fourth quarter of 2006.